As an academic health system, Tampa General Hospital (TGH) leads the way in clinical research and healthcare advancements. Our commitment to providing world-class care is exemplified by our active participation in a wide array of clinical trials. This involvement allows us to offer our patients access to advanced therapies and technologies that they might not have otherwise.
Benefits of Clinical Trials
Clinical trials and research initiatives offer numerous tangible benefits to patients. They provide additional treatment options, especially when no other alternatives exist, and involve patients in the latest medical advancements, contributing to the future of medicine. Participation in clinical trials leads to closer monitoring of clinical care, increased clinic visits, more frequent testing, and potentially free access to diagnostics and therapeutics. Research also integrates seamlessly into patients' multidisciplinary care teams, offering innovative therapeutics and interventions that may otherwise be unavailable. These efforts ultimately translate into improved patient care and outcomes.
Our Clinical Trial History
TGH’s history of clinical trials is rich with research breakthroughs that have significantly benefited patients. Our research on organ preservation following rectal adenocarcinoma has revolutionized rectal cancer treatment. Pioneering work on Regeneron COVID antibodies placed our program at the forefront of pandemic response, enabling rapid deployment of monoclonals and other treatments. The SCENT trial led to the approval of a specialized stent for challenging brain aneurysms, now widely used across the US. Our research has also advanced treatments for various severe diseases, improving patients' quality of life. Notably, our efforts have developed critical reversal agents for medications such as Pradaxa, Xarelto, and Eliquis, innovative HIV and HCV research projects, and essential anti-venom for coral snake bites.
Clinical Trials at TGH Today
TGH’s history of clinical trials is rich with research breakthroughs that have significantly benefited patients. Our research on organ preservation following rectal adenocarcinoma has revolutionized rectal cancer treatment. Pioneering work on Regeneron COVID antibodies placed our program at the forefront of pandemic response, enabling rapid deployment of monoclonals and other treatments. The SCENT trial led to the approval of a specialized stent for challenging brain aneurysms, now widely used across the US. Our research has also advanced treatments for various severe diseases, improving patients' quality of life. Notably, our efforts have developed critical reversal agents for medications such as Pradaxa, Xarelto, and Eliquis, innovative HIV and HCV research projects, and essential anti-venom for coral snake bites.
Mission
To build a healthier future by leveraging the USF TGH partnership to pioneer groundbreaking biomedical research for the betterment of our patients and society at large.
Vision
To be a world leader in biomedical research and therapeutic innovation.
Values
Excellence, Innovation, Moral Integrity, Scientific Rigor, Intellectual Freedom, High-impact Discovery